Speaker Profile
CEO + Co Founder, Aitia
Biography
Colin Hill is a trailblazer in applying causal AI to precision medicine. Aitia, the company he co-founded and leads, has built a powerful Digital Twin discovery and drug development platform, with a current focus on neurodegenerative diseases and oncology. He serves on the boards of Fulcrum Therapeutics (NASDAQ: FULC, a rare genetic disease company, Centrexion Therapeutics, a non-opioid pain therapeutics company, and the Critical Path Institute, which fosters collaborations between scientific and regulatory bodies.He previously served on the boards of mobile health company Biotelemetry Inc., CRO PPD Inc., and sickle cell disease company AesRx.In 2004, Colin was named to MIT Technology Reviews TR100 list of the top 100 innovators in the world under the age of 35. He has appeared in publications and television programs including The Wall Street Journal, CNBC Morning Call SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.
Talk
Gemini Digital Twins Accelerate Precision Medicine
The biggest obstacle to realization of precision medicine is poor knowledge of the complex biological circuitry underlying human health and disease. The convergence of raw computational power, multiomic and clinical data, and causal AI has led to Gemini Digital Twins, in silico circuitry models of virtually any disease (we will discuss Huntington's and prostate cancer).
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, Cytoreason
Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, Biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Sanoj Punnen, University of Miami
• Shivanni Kummar, OHSU
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug?
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
